Chelsea Therapeutics, Inc. Achieves Target Enrollment in Second Pivotal Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension

CHARLOTTE, N.C., Sept. 9, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has successfully reached its target enrollment of 118 randomized patients for Study 301, the second of two pivotal Phase III clinical trials in Chelsea’s registration program of Droxidopa for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH).